DE3486029T2 - Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung. - Google Patents

Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung.

Info

Publication number
DE3486029T2
DE3486029T2 DE19843486029 DE3486029T DE3486029T2 DE 3486029 T2 DE3486029 T2 DE 3486029T2 DE 19843486029 DE19843486029 DE 19843486029 DE 3486029 T DE3486029 T DE 3486029T DE 3486029 T2 DE3486029 T2 DE 3486029T2
Authority
DE
Germany
Prior art keywords
delayed delivery
parental administration
ifn preparation
ifn
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE19843486029
Other languages
English (en)
Other versions
DE3486029D1 (de
Inventor
Yoshiya Yamahira
Keiji Fujioka
Shigeji Sato
Noboru Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP19306483A external-priority patent/JPS6084213A/ja
Priority claimed from JP19718183A external-priority patent/JPS6089418A/ja
Priority claimed from JP58206226A external-priority patent/JPS6097918A/ja
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of DE3486029D1 publication Critical patent/DE3486029D1/de
Publication of DE3486029T2 publication Critical patent/DE3486029T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
DE19843486029 1983-10-14 1984-10-12 Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung. Expired - Fee Related DE3486029T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP19306483A JPS6084213A (ja) 1983-10-14 1983-10-14 徐放性消炎鎮痛製剤
JP19718183A JPS6089418A (ja) 1983-10-20 1983-10-20 徐放性制癌剤
JP58206226A JPS6097918A (ja) 1983-11-01 1983-11-01 インタ−フエロン持続性製剤

Publications (2)

Publication Number Publication Date
DE3486029D1 DE3486029D1 (de) 1993-02-18
DE3486029T2 true DE3486029T2 (de) 1993-05-13

Family

ID=27326713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19843486029 Expired - Fee Related DE3486029T2 (de) 1983-10-14 1984-10-12 Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung.

Country Status (2)

Country Link
EP (1) EP0138216B1 (de)
DE (1) DE3486029T2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1277601C (en) * 1985-12-27 1990-12-11 Shigeji Sato Method for producing sustained release formulation
EP0230654B1 (de) * 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Arzneimittel mit verzögerter stossweiser Freisetzung
NL194638C (nl) * 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
AU606383B2 (en) * 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
FR2619506B1 (fr) * 1987-08-17 1990-08-24 Septodont Procede de fabrication de preparations medicamenteuses solides associant du collagene et un agent anti-infectieux imidazole, ainsi que leur application au traitement d'affections du parodonte
ES2054815T3 (es) * 1987-09-08 1994-08-16 Takeda Chemical Industries Ltd Citoquinas insolubilizadas en agua.
ATE90570T1 (de) * 1988-01-29 1993-07-15 Sumitomo Pharma Verbesserte formulierungen mit kontrollierter abgabe.
FI901046A0 (fi) * 1989-03-17 1990-03-01 Eisai Co Ltd Stabilisering av polyprenylfoereningen.
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
EP0615444B1 (de) * 1991-12-05 1996-03-06 ALFATEC-PHARMA GmbH Perorale applikationsform für peptidarzneistoffe, insbesondere insulin
DK0621777T3 (da) * 1992-01-17 1996-10-21 Alfatec Pharma Gmbh Pellets indeholdende aktivt stof og med en matrix af hydrofile makromolekyler, og fremgangsmåde til deres fremstilling
EP0621775B1 (de) * 1992-01-17 1997-08-06 ALFATEC-PHARMA GmbH Peptidarzneistoffe enthaltende pellets und ihre herstellung sowie deren verwendung
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
WO2005044236A1 (en) * 2003-10-27 2005-05-19 Control Delivery Systems, Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181731A (en) * 1976-09-07 1980-01-01 Sumitomo Chemical Company, Limited Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
NZ195933A (en) * 1980-01-11 1982-11-23 Boots Co Ltd Sustained-release pharmaceutical compositions in tablet form
DE3104815C2 (de) * 1980-02-13 1983-07-07 Japan Atomic Energy Research Institute, Tokyo Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe
EP0090837A1 (de) * 1981-10-08 1983-10-12 BERG, Kurt Frimann Verfahren und zusammensetzung zum behandeln von kranken die an interferon empfindlichen krankheiten leiden
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
ZA836030B (en) * 1983-08-16 1985-02-27 Verex Lab Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions

Also Published As

Publication number Publication date
EP0138216A3 (en) 1985-10-30
DE3486029D1 (de) 1993-02-18
EP0138216B1 (de) 1993-01-07
EP0138216A2 (de) 1985-04-24

Similar Documents

Publication Publication Date Title
DE3486029D1 (de) Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung.
DE3484951D1 (de) Verlaengerte praeparate mit verzoegerter abgabe.
DE3688532T2 (de) Pharmazeutische darreichungsform mit verzoegerter abgabe.
DE3586823D1 (de) Matrize fuer bioaktive zusammensetzung mit dauerverabreichung.
DK553683D0 (da) Praeparat med kontrolleret afgivelse
DE3775483D1 (de) Zubereitung mit verzoegerter freigabe.
DE3676235D1 (de) Arzneizubereitung mit verzoegerter wirkstoffabgabe.
NL7805510A (nl) Farmaceutisch preparaat met vertraagde afgifte.
DE3681348D1 (de) Oral-arzneizubereitung mit retardwirkung.
DK361786A (da) Granulaere farmaceutiske praeparater med forskudt afgivelse
DE3482532D1 (de) Prozessor mit zwangseinstellung.
DK301487D0 (da) Transdermisk indgiftindretning med forsinket virkning
DE3484584D1 (de) Injektionen mit verzoegerter abgabe.
DE3778106D1 (de) Dosierungsform mit verzoegernder freisetzung.
NO881058D0 (no) Hepatocytt rettet vesikkel avleveringssystem.
IL71112A (en) Osmotic system with instant drug availability
DE3782840T2 (de) Arzneimittel mit verzoegerter freigabe.
FI844434L (fi) Stol med stoed foer anvaendarens bakdel respektive ben.
TR21892A (tr) Piridazinon tuerevleri,bunlarin hazirlanmasi ile ensektisid,akarisid,fungisid,nematisid bilesimler
DE3483133D1 (de) Pharmazeutische zusammensetzungen.
DE3485408D1 (de) Pharmazeutische zusammensetzung.
NO166494C (no) Fremgangsmaate for fremstilling av human lymfoblastoid interferon.
FI852804A0 (fi) Farmaceutiska preparat med reglerbar utloesning.
NO160898C (no) Stol.
IT8347560A0 (it) Polipeptide dotato di attivita' di interferon, composizione che lo con tiene e procedimento di preparazione

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee